Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Britain Courts Anthropic Amid US Defense Department Dispute 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
SAN DIEGO, July 26, 2017 -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Apricus’ second quarter 2017 financial results will be released on Wednesday, August 2, 2017 at 4:01 p.m. Eastern Time. Company management will host a conference call on Wednesday, August 2, 2017 at 4:30 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.
To participate by telephone, please dial (855) 780-7196 (Domestic) or (631) 485-4867 (International). The conference ID number is 58725002. The live audio webcast can be accessed via the Investor Relations’ section of Apricus’ website at www.apricusbio.com. Please log in approximately 5-10 minutes before the event to ensure a timely connection. The archived webcast will remain available for 30 days following the live call.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus has two product candidates currently in development. Vitaros is a product candidate in the United States for the treatment of erectile dysfunction, which is in-licensed from Warner Chilcott Company, Inc., now a subsidiary of Allergan plc (Allergan). RayVa is our product candidate in Phase 2 development for the treatment of the circulatory disorder Raynaud’s phenomenon, secondary to scleroderma, for which Apricus owns worldwide rights.
For further information on Apricus, visit http://www.apricusbio.com.
Vitaros™ is Apricus’ trademark in the United States, which is pending registration and subject to the agreement with Allergan. Vitaros® is a registered trademark of Ferring International Center S.A. in certain countries outside of the United States. RayVa™ is Apricus’ trademark, which is registered in certain countries throughout the world and pending registration in the United States.
CONTACT: Institutional / Retail Investors: Matthew Beck [email protected] The Trout Group LLC (646) 378-2933
